Biktarvy is sweeping up patients from Gilead's older HIV meds. (Gilead Sciences)
Biktarvy Company: Gilead Sciences 2019 sales: $4.74 billion Projected 2026 sales: $11.4 billion Projected CAGR: +14% Used for: HIV
Taking the crown as a drugmaker's best launch ever is no easy feat, but that's exactly what three-drug HIV regiment Biktarvy did for Gilead Sciences in its first full year on the market in 2019. Driven by superior efficacy over older, two-drug therapies, Biktarvy could keep pushing into megablockbuster territory in the coming years.
Biktarvy hit $4.74 billion in sales in 2019 and could post impressive 14% annual growth through 2026, Evaluate Pharma forecast. That increase would put Biktarvy at $11.4 billion in sales by that year, among the biggest hauls in pharma.
Within Gilead's extensive HIV portfolio, Biktarvy stands out for its three-drug formulation and also its skyrocketing sales, which have bucked a troubling trend for the drugmaker.